Carey Anders
Assistant Director of Clinical Research
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (26)
Year:
2026
Purpose: Establish the safety, tolerability, and preliminary activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer therapies in human epidermal growth factor receptor 2 (HER2)–low metastatic breast cancer (mBC). Patients and Methods: DESTINY-Breast08 was a two-part, open-label, multicenter, phase Ib study. Patients with locally confirmed HER2-low mBC received T-DXd plus capecitabine, durvalumab + paclitaxel, capivasertib, anastrozole, or fulvestrant. Eligibility criteria for hormone receptor status varied across modules and between study parts. Primary objectives were safety/tolerability and determining recommended phase II doses (RP2D); secondary endpoints included objective response rate (ORR; per investigator). Results: In the dose-finding phase, 37 patients were assigned to a module. RP2Ds were determined for T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant. For strategic reasons, T-DXd + durvalumab + paclitaxel was not pursued beyond the dose-finding phase (n = 3). In the dose-expansion phase, 101 patients were assigned to a module. For T-DXd + capecitabine, grade ≥3 adverse events (AE) occurred in 55% (11/20) of patients, and the ORR was 60%. For T-DXd + capivasertib, grade ≥3 AEs occurred in 67.5% (27/40) of patients, and the ORR was 60%. For T-DXd + anastrozole, grade ≥3 AEs occurred in 47.6% (10/21) of patients, and the ORR was 71.4%. For T-DXd + fulvestrant, grade ≥3 AEs occurred in 55% (11/20) of patients, and the ORR was 40%. Adjudicated drug-related interstitial lung disease/pneumonitis events were reported for T-DXd + capecitabine (3/20; grade 2, n = 2; grade 5, n = 1), T-DXd + capivasertib (8/40; all grade ≤2), and T-DXd + fulvestrant (5/20; all grade 2). Conclusions: Safety results were generally consistent with known individual profiles for T-DXd and combination drugs. T-DXd plus capecitabine, capivasertib, anastrozole, or fulvestrant demonstrated preliminary clinical activity in patients with HER2-low mBC.
Year:
2026
Year:
2025
Year:
2025
Brain metastases (BrM) arising from solid tumors is an ever-increasing and often devastating clinical challenge impacting hundreds of thousands of patients annually worldwide. As systemic anticancer therapies, and thus survival, improve, the risk for central nervous system (CNS) recurrence has increased. Historically, patients with BrM were excluded from clinical trials; however, there has been a shift toward increasing inclusion over the past decade. To most effectively design the next generation of clinical trials for patients with BrM, a multidisciplinary team spanning local and systemic therapies is imperative. CIMARa (Consortium for Intracranial Metastasis Academic Research), formalized in June 2021, is an inclusive group of multidisciplinary clinical investigators, research scientists, and advocates who share the collective goal of improving outcomes for patients with BrM. CIMARa aims to improve outcomes through the development, coordination, and awareness of multi-institutional clinical trials testing novel therapeutic agents for this unique patient population alongside the translation of preclinical research to the clinical setting.
Year:
2025
Background: Development of new melanoma therapies has increased survival, and more patients are living to develop brain metastasis (BrM). Identifying those at increased risk of BrM is of significant public health importance, and our objective was to assess the relationship between atopy and survival or reduced BrM cumulative incidence (CI) in melanoma. Methods: This retrospective study was conducted in individuals (≥66 years) in linked Surveillance, Epidemiology, and End Results and Medicare data. History of atopy diagnosed prior to melanoma was ascertained using International Classification of Diseases-9/10 codes. Associations between atopy, CI of BrM, and overall survival were assessed using cox proportional hazards models to estimate hazard ratios and P values. Results: A total of 23,508 cutaneous melanoma cases were identified. Overall, 6.1% developed BrM, and 38% had history of atopy. Atopy was associated with an 18% decrease in death (P < 0.001). Among those without metastasis at diagnosis, atopy decreased BrM CI by 16% (P = 0.006). Among those with metastasis at diagnosis (any site), only those who received checkpoint inhibitors had a suggestive but nonsignificant survival with atopy. Conclusions: Atopy confers improved survival and decreased BrM CI. History of atopy in the elderly may identify those with more robust immune function that may be more responsive to treatment. Impact: Elderly individuals with prior diagnosis of atopy had significantly improved survival and decreased incidence of BrM as compared with individuals without atopy. This suggests that history of atopy may identify a subgroup within melanoma with improved response to treatment and a more robust immune system.
Year:
2025
Year:
2025
Year:
2025
Background Melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biological features and clinical outcomes of MBM will facilitate the design of rational therapies. Methods We examined the mutational landscape and gene expression profiles of MBM (74 patients) and ECM (34 patients) in paired patient samples from a previously published dataset with whole-exome sequencing (WES) and RNA sequencing (RNAseq) data from MD Anderson Cancer Center (MDACC). We also present findings from MBM from a new cohort of 14 patients from Duke University to strengthen investigation of somatic mutations and gene expression profiles. Gene Set Enrichment Analysis (GSEA) was used to compare paired MBM versus lymph node (LN) metastases and skin metastases. Relative immune cell abundance was inferred using deconvolution methods. Survival outcomes from craniotomy and associations with biological features, BRAF mutation status, and PTEN expression were assessed. Results GSEA found that autophagy signaling pathways are enriched in MBM versus LN and skin metastases. BRAF was the most frequently mutated clinically relevant gene in MBM and ECM, with NRAS and PTEN also frequently altered in MBM. The most strongly upregulated genes in autophagy pathways were glial fibrillary acidic protein ( GFAP ) and hemoglobin beta ( HBB ). An increased proportion of immune-suppressive M2 compared to tumor-suppressive M1 macrophages in MBM and ECM was identified. There was not sufficient evidence for an association between BRAF V600 mutation status or expression and overall survival (OS) from craniotomy. Conclusions The mutational landscape and gene expression of MBM from the Duke cohort resembled those previously reported in the MDACC cohort. Upregulation of autophagy pathways was observed in patient-matched MBM versus LN and skin metastases due to upregulation of two genes, GFAP and HBB . In MBM, higher M2:M1 ratio may contribute to a therapeutically relevant immune-suppressive tumor microenvironment (TME).
Year:
2025
Background Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous system (CNS) recurrence. The genomic alterations driving CNS recurrence, along with contributions of the immune microenvironment, particularly by intrinsic subtype, remain unclear. Methods We characterized the genomic and immune landscape of BCBrM from a cohort of 42 patients by sequencing whole-exome DNA (WES) and total RNA libraries from frozen and FFPE BrM and FFPE extracranial tumors (ECT). Analyses included PAM50 intrinsic subtypes, somatic mutations, copy number variations (CNV), pathway alterations, immune cell type deconvolution, and associations with clinical outcomes Results Intrinsic subtype calls were concordant for the majority of BrM-ECT pairs (60%). Across all BrM and ECT samples, the most common somatic gene mutation was TP53 (64%, 30/47). For patients with matched FFPE BrM-FFPE ECT, alterations tended to be conserved across tissue type, although differential somatic mutations and CNV in specific genes were observed. Several genomic pathways were differentially expressed between patient-matched BrM-ECT; MYC targets, DNA damage repair, cholesterol homeostasis, and oxidative phosphorylation were higher in BrM, while immune-related pathways were lower in BrM. Deconvolution of immune populations between BrM-ECT demonstrated activated dendritic cell populations were higher in BrM compared to ECT. Increased expression of several oncogenic preselected pathways in BrM were associated with inferior survival, including DNA damage repair, inflammatory response, and oxidative phosphorylation Conclusions Collectively, this study illustrates that while some genomic alterations are shared between BrM and ECT, there are also unique aspects of BrM including somatic mutations, CNV, pathway alterations, and immune landscape. A deeper understanding of differences inherent to BrM will contribute to the development of BrM-tailored therapeutic strategies. Additional analyses are warranted in larger cohorts, particularly with additional matched BrM-ECT.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (38)
Kouros Owzar
Professor
Duke University
Ajay Dhakal
Associate Professor
University of Rochester
scott floyd
Associate Professor
Duke University
Rebecca Shatsky
Associate Professor of Medicine
University of California San Diego School of Medicine
Mark Gilbert
Branch Chief
Medical University of South Carolina
Sherene Loi
University of Melbourne
Young-Hyuck Im
Sungkyunkwan University School of Medicine
Peter E. Fecci
Chair and Professor
Duke University Medical Center
Soma Sengupta
Chair
Tufts Medical Center
Aglaia Schiza
Associate Professor (Docent, non-tenured and unsalaried title in the Swedish system)
Uppsala University
Guy Jerusalem
-
Yara G Abdou
University of North Carolina at Chapel Hill
Nelson Moss
Memorial Sloan Kettering Cancer Center
Alexandra S. Zimmer
-
Nancy Lin
Associate Professor of Medicine
Dana-Farber Cancer Institute
Jordan M. Komisarow
Duke University
Diana M Cittelly
Associate Professor
University of Colorado Anschutz Medical Campus
Quinn Ostrom
Assistant Professor
Duke University School of Medicine
Rebecca Dent
Head/Senior Consultant
National Cancer Center
Karen Lisa Smith
Johns Hopkins University School of Medicine
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Laura Alder
Duke University
Priscilla Brastianos
Director of Brain Metastasis Center, Massachusetts General Hospital
Harvard University
Stanley Lipkowitz
Chief
National Cancer Institute
Scott L. Carter
-
Eric Burton
National Cancer Institute
Kyle Walsh
Duke University
Sarah Sammons
Assistant Professor
Dana-Farber Cancer Institute
Sheheryar Kabraji
Associate Professor
Roswell Park Comprehensive Cancer Center
Sung-Bae Kim
University of Ulsan College of Medicine
Jill S Barnholtz-Sloan
Duke University School of Medicine
Jacek Jassem
professor
Medical University of Gdansk
April K.S. Salama
Duke University Medical Center
Melinda L Telli
Professor of Medicine
Stanford University School of Medicine
J. Neman
-
Alexandra Thomas
Associate Director for Translational Science
Duke University
Sarah Jenkins
Clinical Assistant Professor
University of Tennessee Medical Center
William D Figg
Senior Investigator, Lab Chief, Associate Director
National Institutes of Health
Make your next move.
Prepare your application
Review drafts before you send them.